8-K: ImmuCell Announces Record First Quarter Sales, Up 111% Year-Over-Year

ImmuCell Corporation reported a record $7.3 million in sales for the first quarter of 2024, a 111% increase compared to the same period last year.

Summary

• ImmuCell Corporation announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024.
• Total sales for the quarter reached $7.3 million, a 111% increase compared to $3.4 million in the first quarter of 2023.
• This represents a 42% increase compared to the $5.1 million in sales recorded in the previous quarter (Q4 2023).
• The company also reported a 33% increase in sales for the twelve-month period ending March 31, 2024, with total sales of $21.3 million compared to $16.0 million in the prior year.
• The $7.3 million in sales is an all-time quarterly sales record for the company, exceeding the previous high of $6 million in Q1 2022 by 21% or $1.3 million.
• The company's order backlog was approximately $9.1 million as of March 31, 2024, a slight decrease from $9.4 million as of December 31, 2023, but still significantly higher than the $2.5 million as of December 31, 2022.
• ImmuCell is awaiting a response from the FDA regarding their third submission for Re-Tain, expected no later than May 2024.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the record sales, significant growth, and high order backlog. The company's progress with Re-Tain also contributes to the positive outlook.

Positives

• The company achieved record quarterly sales, demonstrating strong demand for its products.
• The significant year-over-year and quarter-over-quarter sales growth indicates positive market traction.
• The high order backlog suggests continued strong demand and potential for future revenue.
• The company is progressing with the regulatory approval process for Re-Tain.

Negatives

• The order backlog decreased slightly from $9.4 million to $9.1 million, indicating a potential challenge in fulfilling orders.
• The company is still awaiting FDA approval for Re-Tain, which introduces uncertainty.

Risks

• The company faces risks related to the timing and outcome of regulatory approvals, particularly for Re-Tain.
• There are risks associated with managing the high order backlog and ensuring timely production.
• The company is subject to competition within its product markets.
• Supply chain disruptions could adversely impact operations and customer relationships.
• There are commercial and operational risks related to the expansion of production capacity.

Future Outlook

The company expects to continue providing preliminary sales reports after the close of each quarter. They are also focused on increasing production output to meet demand and are awaiting FDA approval for Re-Tain.

Management Comments

• The $7.3 million in total product sales achieved during the first quarter of 2024 is an all-time quarterly sales record for us, commented Michael F. Brigham, President and CEO of ImmuCell.
• As the work to increase production output to meet demand continues, the backlog of orders was worth approximately $9.1 million as of March 31, 2024.
• In addition, we continue to work to achieve FDA approval to commercialize Re-Tain, Mr. Brigham concluded.

Industry Context

The animal health industry is experiencing growth, and ImmuCell's focus on dairy and beef cattle health aligns with this trend. The development of Re-Tain, a non-antibiotic treatment for mastitis, addresses a growing need for alternatives to traditional antibiotics in livestock farming.

Comparison to Industry Standards

• ImmuCell's 111% year-over-year sales growth in Q1 2024 is significantly higher than the average growth rate for many companies in the animal health sector.
• Companies like Zoetis and Elanco, which are larger players in the animal health market, typically experience more moderate growth rates.
• The high backlog of orders suggests that ImmuCell's products are in high demand, potentially indicating a competitive advantage in their niche market.
• The development of Re-Tain, with its no milk discard claim, could be a significant differentiator compared to traditional antibiotic treatments for mastitis offered by competitors.

Stakeholder Impact

• Shareholders will likely react positively to the record sales and strong growth.
• Employees may benefit from the company's success and growth.
• Customers are likely to be impacted by the high demand and potential backlog.
• Suppliers may see increased demand for their products due to ImmuCell's growth.

Next Steps

• The company will host a conference call on May 10, 2024, to discuss the Q1 2024 financial results.
• ImmuCell is awaiting an FDA response regarding Re-Tain by May 2024.
• The company will continue to work on increasing production output to meet demand.

Key Dates

Keywords

ImmuCell, animal health, dairy cattle, beef cattle, First Defense, Re-Tain, sales, revenue, FDA approval, backlog, mastitis